These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35398617)

  • 1. Exosomal-microRNA transcriptome profiling of Parental and CSC-like MDA-MB-231 cells in response to cisplatin treatment.
    Koh MZ; Ho WY; Yeap SK; Ali NM; Yong CY; Boo L; Alitheen NB
    Pathol Res Pract; 2022 May; 233():153854. PubMed ID: 35398617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin-resistant MDA-MB-231 Cell-derived Exosomes Increase the Resistance of Recipient Cells in an Exosomal miR-423-5p-dependent Manner.
    Wang B; Zhang Y; Ye M; Wu J; Ma L; Chen H
    Curr Drug Metab; 2019; 20(10):804-814. PubMed ID: 31424364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of Cellular and Cancer Stem Cell-Related Putative Gene Expression of Parental and CD44
    Koh MZ; Ho WY; Yeap SK; Ali NM; Boo L; Alitheen NB
    Pharmaceuticals (Basel); 2021 Apr; 14(5):. PubMed ID: 33919109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer.
    Ouyang M; Li Y; Ye S; Ma J; Lu L; Lv W; Chang G; Li X; Li Q; Wang S; Wang W
    PLoS One; 2014; 9(5):e96228. PubMed ID: 24788655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SOD1-high fibroblasts derived exosomal miR-3960 promotes cisplatin resistance in triple-negative breast cancer by suppressing BRSK2-mediated phosphorylation of PIMREG.
    Li K; Lin H; Liu A; Qiu C; Rao Z; Wang Z; Chen S; She X; Zhu S; Li P; Liu L; Wu Q; Wang G; Xu F; Li S
    Cancer Lett; 2024 May; 590():216842. PubMed ID: 38582395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation.
    Drago-Ferrante R; Pentimalli F; Carlisi D; De Blasio A; Saliba C; Baldacchino S; Degaetano J; Debono J; Caruana-Dingli G; Grech G; Scerri C; Tesoriere G; Giordano A; Vento R; Di Fiore R
    Oncotarget; 2017 Apr; 8(17):28939-28958. PubMed ID: 28423652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes.
    Liu Y; Cai Q; Bao PP; Su Y; Cai H; Wu J; Ye F; Guo X; Zheng W; Zheng Y; Shu XO
    Breast Cancer Res Treat; 2015 Jul; 152(1):183-191. PubMed ID: 26062749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis.
    Qattan A; Al-Tweigeri T; Alkhayal W; Suleman K; Tulbah A; Amer S
    Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33918859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exosomal transfer of miR-106a-5p contributes to cisplatin resistance and tumorigenesis in nasopharyngeal carcinoma.
    Li J; Hu C; Chao H; Zhang Y; Li Y; Hou J; Huang L
    J Cell Mol Med; 2021 Oct; 25(19):9183-9198. PubMed ID: 34469038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Withaferin A alters the expression of microRNAs 146a-5p and 34a-5p and associated hub genes in MDA-MB-231 cells.
    Shuaib M; Chaudhri S; Kumar S
    Biomol Concepts; 2024 Jan; 15(1):. PubMed ID: 38525814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptome Profiling of Cisplatin Resistance in Triple-negative Breast Cancer: New Insight into the Role of PI3k/Akt Pathway.
    Memar M; Farazmandfar T; Sabaghian A; Shahbazi M; Golalipour M
    Curr Mol Med; 2023; 23(6):559-568. PubMed ID: 35585821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24.
    Li Z; Meng Q; Pan A; Wu X; Cui J; Wang Y; Li L
    Oncotarget; 2017 Mar; 8(12):19455-19466. PubMed ID: 28038450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dihydrotestosterone Induces Chemo-Resistance of Triple-Negative Breast MDA-MB-231 Cancer Cells Towards Doxorubicin Independent of ABCG2 and miR-328-3p.
    Al-Momany B; Hammad H; Ahram M
    Curr Mol Pharmacol; 2021; 14(5):860-870. PubMed ID: 34061013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of carcinogenic potential-associated molecular mechanisms in CD133(+) A549 cells based on microRNA profiles.
    Chen QY; Jiao DM; Zhu Y; Hu H; Wang J; Tang X; Chen J; Yan L
    Tumour Biol; 2016 Jan; 37(1):521-30. PubMed ID: 26227219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-199a-3p enhances breast cancer cell sensitivity to cisplatin by downregulating TFAM (TFAM).
    Fan X; Zhou S; Zheng M; Deng X; Yi Y; Huang T
    Biomed Pharmacother; 2017 Apr; 88():507-514. PubMed ID: 28126676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiRNA Transcriptome Profiling of Spheroid-Enriched Cells with Cancer Stem Cell Properties in Human Breast MCF-7 Cell Line.
    Boo L; Ho WY; Ali NM; Yeap SK; Ky H; Chan KG; Yin WF; Satharasinghe DA; Liew WC; Tan SW; Ong HK; Cheong SK
    Int J Biol Sci; 2016; 12(4):427-45. PubMed ID: 27019627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway.
    Liu M; Yang J; Lv W; Wang S; Du T; Zhang K; Wu Y; Feng X
    Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34935899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
    Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
    Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of exosomal miR-9 and miR-155 targeting PTEN and DUSP14 in highly metastatic breast cancer and their effect on low metastatic cells.
    Kia V; Paryan M; Mortazavi Y; Biglari A; Mohammadi-Yeganeh S
    J Cell Biochem; 2019 Apr; 120(4):5666-5676. PubMed ID: 30335891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic Index of Sensitivity to Chemotherapy for Triple Negative Breast Cancer.
    Sameer C A; Shah M; Nandy D; Gupta R
    Asian Pac J Cancer Prev; 2023 Jun; 24(6):2043-2053. PubMed ID: 37378935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.